David W. Addis

Covington & Burling (Washington)
Lawyer (of Counsel)

David Addis’s practice encompasses US foreign trade controls, including export controls, technology controls and encryption regulation, and antitrust counseling on mergers and acquisitions, joint ventures and other competitor collaborations, and intellectual property licensing, including IP licensing policies for standard-setting organizations. Mr. Addis has extensive experience with US foreign trade controls, export regulations and embargo sanctions administered by the Departments of Commerce, Treasury, State and Homeland Security, and advises on compliance, obtaining licensing, and responding to possible enforcement actions.

Linked authors

Covington & Burling (Washington)
Covington & Burling (Washington)
Covington & Burling (Washington)
Covington & Burling (Washington)
Covington & Burling (Washington)
Covington & Burling (Washington)
Covington & Burling (San Francisco)
Covington & Burling (Washington)

Articles

106 Bulletin

David W. Addis, James Dean, John D. Graubert, Timothy C. Hester, James J. O’Connell The US FTC adopts new rules clarifying HSR filing requirements for transfers of pharmaceutical patent rights

16

On November 6, the Federal Trade Commission (“FTC”) amended the implementation rules of the Hart Scott Rodino Antitrust Improvements Act (the “HSR Act”) to specify when parties to pharmaceutical patent license agreements must observe the HSR Act’s notification and pre-closing waiting period (...)

Thomas O. Barnett, James Dean, Deborah A. Garza, John D. Graubert, James J. O’Connell, Anita F. Stork, David W. Addis The US DoJ and FTC announce changes to the HSR Act merger notification process and transaction report form submitted by companies

20

On July 7, 2011, the Federal Trade Commission and the Department of Justice (“the Agencies”) announced significant changes to the form and accompanying materials that companies must submit when reporting transactions under the Hart-Scott-Rodino Antitrust Improvements Act (“HSR Act”). Although the (...)

David W. Addis, Evan R. Cox, John D. Graubert, Theodore Voorhees Jr The US Court of Appeal for the District of Columbia Circuit holds that the avoidance of a RAND commitment leading to higher prices for licenses does not by itself amount to anticompetitive harm (Rambus)

18

On April 22nd, the DC Circuit Court of Appeals set aside the FTC’s 2006 decision that Rambus Inc. unlawfully monopolized four technology markets through deceptive conduct during the JEDEC standards development process for two widely-implemented computer memory standards. The Court held that (...)

Michael Labson, Geoffrey Hobart, Eric Holder, Mark Lynch, Richard Kingham, Peter Safir, Theodore Voorhees Jr, James Dean, David W. Addis, Ethan M. Posner The US FTC announces its intention to conduct an extensive study of the economic effects of authorized generic pharmaceuticals

18

On April 4, 2006, the FTC published notice of its intention to conduct an extensive study of the economic effects of authorized generic pharmaceuticals. See 71 Fed. Reg. 16,779 (April 4, 2006). The initial stage of the study would involve detailed information requests, akin to subpoenas, to as (...)

Send a message